Enhanced Enterococcus gallinarum Flagellin Polypeptide-Based Compositions and Methods

The present inventive concept relates to improved compositions and methods utilizing Enterococcus gallinarum flagellin polypeptides, enhancing immune responses and host defence against infections, while addressing limitations of existing formulations.

The original patent disclosed pharmaceutical compositions comprising isolated Enterococcus flagellin polypeptides for treating diseases. However, these compositions may have limitations in terms of uptake by antigen-presenting cells, half-life in the host, and immune response. The present inventive concept addresses these limitations by introducing delivery agents, modifying the polypeptide sequence, and combining with TLR5 agonists or second therapeutic agents, thereby enhancing the efficacy of the compositions and methods.

The inventive concept encompasses various embodiments, including a method for enhancing immune response by administering a pharmaceutical composition containing a therapeutically effective amount of the polypeptide and a delivery agent, a system for stimulating host defence using a vector encoding a modified flagellin polypeptide, a pharmaceutical composition comprising the polypeptide and a TLR5 agonist for oral administration, a method for treating infections by combining the polypeptide with a second therapeutic agent, and a recombinant vector for expressing the polypeptide with a secretion signal. These embodiments improve upon the original patent by increasing uptake, half-life, and immune response, providing more effective treatment options for Enterococcus gallinarum infections.

The present inventive concept introduces novel combinations and modifications of the original patent's flagellin polypeptides, including the use of delivery agents, TLR5 agonists, and second therapeutic agents, which are not obvious from the original patent. The inventive concept's emphasis on enhancing immune response, host defence, and treatment efficacy sets it apart from the original patent's disclosure.

Alternative embodiments of the inventive concept may include different delivery agents, such as liposomes or nanoparticles, or various TLR5 agonists and second therapeutic agents. The inventive concept may also be adapted for use in different host species or for treating other diseases caused by Enterococcus gallinarum.

The present inventive concept has significant commercial potential in the development of novel therapeutic compositions and methods for treating Enterococcus gallinarum infections, particularly in the fields of human health and animal husbandry. The target market includes pharmaceutical companies, biotechnology firms, and research institutions focused on infectious disease treatment and prevention.